Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.


BACKGROUND IPX066, an investigational extended-release carbidopa-levodopa (CD-LD) preparation, has demonstrated a rapid attainment and prolonged maintenance of therapeutic LD plasma concentrations in advanced Parkinson's disease (PD). This phase-3 crossover study assessed its efficacy and safety vs. CD-LD plus entacapone (CL + E). METHODS At baseline, all… (More)
DOI: 10.1016/j.parkreldis.2014.08.004


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics